Abstract 4-Aminosalicylic acid (4-ASA) has been suggested as an effective treatment for both active and quiescent ulcerative colitis. 5-Aminosalicylic acid (5-ASA) is well accepted for the maintenance treatment of inactive ulcerative colitis. Moreover, recent studies suggest that 5-ASA may also be effective in maintaining remission in Crohn's colitis. As treatment with 4-ASA may result in less side effects, the efficacy of a one year's maintenance treatment with oral 4-ASA (1. 
There were no statistical differences between the 4-ASA and the 5-ASA groups regarding the height of rise in CDAI or of soluble interleukin 2 4 -Aminosalicylic acid (4-ASA), also named para-aminosalicylic acid, is an agent, well known as a comparatively safe drug from its use in high doses for the treatment of tuberculosis over many years. It is an isomer of 5-aminosalicylic acid (5-ASA), which is the active component of the salazosulphapyridine molecule in the treatment of inflammatory bowel disease (IBD). 5-ASA compounds are presently used for the treatment of both moderately active Crohn's diseasel-4 and active ulcerative colitis.5-7 It has been shown that 5-ASA is also effective in maintaining remission in patients with ulcerative colitis,7 8 whereas its value for maintenance treatment of quiescent Crohn's disease is disputed: some authors see no significant difference in the rate of relapse between 5-ASA and placebo,9 10 whereas in other trials 5-ASA may be effective in maintaining remission.11-13 The efficacy of 5-ASA, however, in the maintenance of remission in Crohn's disease may be higher in ileal disease'3 or when given during the first three months after remission was achieved. 12 In comparison with 5-ASA, the sodium salt of 4-ASA is a more stable compound.14 15 Animal models led to the conclusion that 4-ASA may have anti-inflammatory properties comparable with those of 5-ASA. (3) or non-compliance (17) . Careful analysis showed that none of them left the study because of an inflammatory relapse. Neither the per protocol (40 patients) or the intention to treat analysis (60 patients) showed any statistical differences between the 4-ASA and the 5-ASA group (Fig 1) . Of Trial duration (m) Figure 1 : Life three months 21% (4/19) patients in the 4-ASA group and 14% (3/21) patients in the 5-ASA group had suffered from a relapse, at six months 32% of the 4-ASA patients and 29% in the 5-ASA group (six patients in each group) had relapsed, and at 12 months in 36% (7/19) patients receiving 4-ASA and in 38% (8/21) patients receiving 5-ASA a relapse was seen. No statistically significant differences regarding disease history or localisation were seen between patients representing treatment failures and those remaining successfully in remission (data not shown).
The drop out patients as well as those excluded, who developed progressive stenoses, could also represent a subgroup of treatment failures (Fig 1) . We therefore attempted to analyse the course of these patients. Eleven of 20 patients who had not completed the trial for the reasons stated above had been randomised to 4-ASA and 9 of 20 patients received 5-ASA. Of the three patients who had developed progressive stenoses, two received 4-ASA, one was in the 5-ASA group. All three patients developing stenoses had colonoscopy and no significant mucosal inflammation was seen. Moreover, we did not see a rise in the CDAI of more than 50 points and the laboratory constellation (C reactive protein, erythrocyte sedimentation rate, soluble interleukin 2 receptor) did not suggest an acute inflammatory relapse. All 17 patients who had missed their appointments, have been contacted. None of them had left the study because of a rise of activity within four weeks of leaving the trial, which would have qualified them as a treatment failure.
We were interested to find out if the clinical severity of relapse was different between those patients treated with 4-ASA and those receiving 5-ASA. We therefore assessed the average rise in CDAI scores before and after relapse in a per protocol analysis of both groups. The CDAI values mean (SEM) of the relapsing patients treated with 4-ASA increased by 132 (36) points whereas the 5-ASA group showed an average rise of 147 (40) points. Moreover, average endoscopic scores mean (SEM) in those patients relapsing were not different between both treatment groups (3-1 (1L2) for 4-ASA and 3-5 (0 9) for 5-ASA treated patients). We also checked if disease activities were different between patients successfully maintaining remission receiving 4-ASA in comparison with those receiving 5-ASA. Again, no difference in CDAI scores was seen between both groups of quiescent patients (83-3 (29) and 60-9 (23.4) points, respectively).
Immunological parameters including serum soluble interleukin 2 (Fig 2) . Both Patients were grouped into those with a CDAI <100 (n =21, sIL2R: 527 (28 3) (mean (SEM)), from 100 to 200 (n = 7, sIL2R: 787 (92 2), p = 0-002 compared with the patients with a CDAI <100) and those with a CDAI >200 (n = 11, sIL2R: 1003 (79 9), p<0 001 compared with the patients with a CDAI <100). The error bars show mean (SEM). serum soluble interleukin 2 receptor concentrations (mean (SEM)) during relapse (286 (48) U/ml (4-ASA) and 242 (54) U/ml 5-ASA)) and the concentrations of activated T cells 10-1 (3.4)% (4-ASA) and (4)% (5-ASA) were similar in both groups. The increase in soluble interleukin 2 receptor concentrations during relapse was statistically significant (p<0 01), when compared with interleukin 2 receptor values of clinically quiescent patients reaching the one year study end point (Fig 2) .
Moreover, serum concentrations of soluble interleukin 2 receptors correlated in this study with clinical disease activity (Fig 2) . When patients were grouped in those with a CDAI < 100, with a CDAI from 100 to 200, and those with a CDAI >200 the average serum soluble interleukin 2 receptor concentrations were significantly different (Fig 2) . A linear regression analysis calculated a correlation coefficient of 0-732 between the soluble interleukin 2 receptor measurements shown in Fig 2 and A correlation of serum soluble interleukin 2 receptor concentrations to disease activity has been suggested by a number of studies. 23 25-27 The use of serum soluble interleukin 2 receptor concentrations in this study underlines the concept that assessment of this molecule from frozen serum samples may be used to objectively determine and monitor disease activity in clinical trials.
4-Aminosalicylic acid differs from 5-ASA in that it is more stable than 5-ASA, which is substituted in meta position and which therefore brakes down more rapidly in a water solution. '4 15 In contrast with 5-ASA no nephrotoxicity related to 4-ASA has been reported. The only other study that compared these two compounds examined the response to topical treatment in left sided colitis and showed that 4-ASA and 5-ASA were equally effective. 19
The anti-inflammatory mechanism by which the aminosalicylates exert their therapeutic action is unknown. 5-Aminosalicylic acid is a potent inhibitor of arachidonic acid metabolism, decreasing the synthesis of both leukotrienes and prostaglandins. 28 37 38 We therefore speculate that 4-ASA may be used at much higher doses as a slow release formulation and might have a much higher therapeutic efficacy in IBD than seen in this and previous studies.
We concluded that oral 4-ASA treatment may be as effective as 5-ASA in the maintenance of remission in Crohn's disease. Moreover, several studies have suggested that 4-ASA may be effective in the treatment of active Crohn's disease or ulcerative colitis both as a topical formulation (enema) or as an oral slow release tablet. Further placebo controlled trials including a large number of patients are warranted to further investigate this promising compound.
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